We studied the long-term outcome of 87 adults with acute leukemia (age 15-59 years at transplant, median 27; 44 myeloid, 42 lymphoblastic, one biphenotypic) who were alive in continuous remission 2 years after a marrow (n = 74) or blood stem cell (n = 13) autograft. Nine relapsed 25-50 months (median 38) after transplantation. Five relapses were straightforward with no karyotypic or morphologic evolution of the original disease. Four recurrences were unusual, with development of myelodysplasia (n = 3) or myeloproliferative disease (n = 1). Five patients died of relapsed disease and four are still alive. Two patients died of complications related to the transplant, and one of ischemic heart disease. Seventy-nine patients (91%) are alive in remission 24-149 months (median 67) after transplantation (75 in continuous remission and four after further therapy) with Karnofsky scores of 80-100% (median 100%). The 8-year probabilities of survival, toxic death, and relapse (from the 2-year mark) are 89%, 3% and 12%. Eleven (12%) survivors had creatinine levels of Ͼ110 mol/l (one more than double), and 14 (16%) had bilirubin levels of Ͼ17 mmol/l (one more than double) at the last follow-up. None of the following factors was found to be predictive for survival, non-relapse death, or relapse from the 2-year mark in multivariate analysis: age, sex, type of leukemia, disease stage, diagnosis, conditioning, origin of cells, and nucleated cell dose. We conclude that adult patients with acute leukemia who are alive and well 2 years following an autograft have a high probability of being cured, and the incidence of long-term liver and kidney dysfunction measured by serum bilirubin and creatinine is low.
geneic transplantation. [1] [2] [3] Toxic deaths usually occur early after autologous transplantation, 1, 2 and, unlike the situation following, an allograft, [4] [5] [6] it is unusual to encounter late TRM in acute leukemia patients who are alive and well 2 years after autotransplantation. 5 Relapse is a relatively uncommon event beyond 2 years after autografting for acute leukemia, 1, 2 and patients are often considered cured at 2-5 years. 4 This review was undertaken to determine the long-term outcome of adult patients with acute leukemia who were alive and well in continuous remission 2 years after autologous blood or marrow transplantation (BMT).
Patients and methods
The Leukaemia Unit database of the Royal Marsden Hospital 7, 8 contains comprehensive data on all patients treated in the Unit which are collected prospectively (ie in real time). These data were searched to identify patients with acute leukemia who were 15 years of age or older at the time of autologous bone marrow or peripheral blood stem cell transplantation, and who were alive in continuous remission 2 years after transplantation. Patients received autologous hematopoietic rescue after primary failure of alloengraftment. 9 Patient characteristics are shown in Table 1 . The data were analyzed as of April 1997, and therefore included only patients transplanted before April 1995.
Conditioning regimens
The various conditioning regimens used have been described before and varied in accordance with practices prevalent in the unit at the time. 1, 2, [9] [10] [11] [12] In patients receiving total body irradiation (TBI) as part of the conditioning regimen, single-fraction (950, 1050 or 1150 cGy) TBI was delivered from opposed 60 Co sources at a low rate (4 cGy/min). The regimens used included: 110 or 140 mg/m 2 melphalan with single-fraction TBI, 16 mg/kg busulfan with 120 or 200 mg/kg cyclophosphamide or 140 mg/m 2 melphalan, or 200 mg/m 2 melphalan alone (Table 1) .
Post-transplant therapy
Maintenance cytotoxic chemotherapy with 6-mercaptopurine and methotrexate was given for 2 years after adequate hematologic recovery following autotransplantation in patients with acute lymphoblastic leukemia (ALL). Patients with AML did not receive any chemotherapy routinely. Thus, ALL patients who were alive and well at the 2-year mark were almost invariably on 6-mercaptopurine and methotrexate at the 2-year mark, and remained on these agents for a few weeks more.
Antimicrobial prophylaxis
No antimicrobial prophylaxis was employed routinely beyond 2 years except in patients who had received TBI as part of the conditioning regimen who received life-long prophylaxis against pneumococcal sepsis with penicillin or erythromycin. 14,15 ALL patients, who received maintenance chemotherapy for 2 years following transplantation, were usually on this at the 2-year mark and received trimethoprim-sulfamethoxazole for prophylaxis against Pneumocystis carinii pneumonia.
Assessment of liver and kidney function
In addition to blood counts, serum biochemical parameters were measured at each visit. Assessment of liver and kidney function was based upon serum alanine aminotransferase (ALT), alkaline phosphatase (AP), bilirubin and creatinine values at the time of the last follow-up in remission. Creatinine clearance was not routinely measured.
Treatment of relapse
This was variable, and depended upon the patient's clinical condition and the tempo of disease recurrence. 16 Patients with ALL who were electively autografted with bloodderived cells in first remission underwent, by design, a T cell non-depleted allograft in second remission after conditioning with etoposide (60 mg/kg) and TBI (1050 cGy). 12 Other patients, including those treated with TBI for the autograft, were potentially considered eligible for a second transplant (autologous or allogeneic). 16 
Statistical considerations
The actuarial probabilities of overall survival, transplantrelated mortality (toxic death), and relapse were calculated from the 2-year mark following BMT. In computing overall survival, all deaths irrespective of cause (n = 8) were considered events and living patients (n = 79) were censored at the last follow-up. In computing toxic deaths, all transplantrelated deaths (n = 2) were considered events, while patients living in continuous remission (n = 75) were censored at the last follow-up, relapsed patients (n = 9) were censored at the time of relapse, and one patient dying of a cause unrelated to the disease or the transplant (Table 2) was censored at the time of death. In computing relapse, all relapses (n = 9) were considered events, while patients living in continuous remission (n = 75) were censored at the last follow-up, and patients dying of toxicity (n = 2) or unrelated causes (n = 1) were censored at the time of death.
The following factors were studied in a multivariate fashion based on Cox's proportional hazards model for their independent contribution to non-relapse mortality, relapse rates, and overall survival from the 2-year mark after BMT: age, sex, diagnosis, stage, conditioning regimen, the source of cells (blood vs marrow), and the nucleated cell dose.
Results

Relapse
Nine patients (10%, five AML, four ALL) relapsed 25-50 months (median 38) after BMT (corresponding to 1-26 months, median 14, after the 2-year mark). Five patients died of relapsed disease. One ALL patient is alive 8 months after an allograft from an HLA-matched sibling, 12, 13 and three are in remission after reinduction chemotherapy. The actuarial probability of relapse at 8 years from the 2-year mark is 12% (Figure 1 ).
Unusual patterns of disease recurrence
Five of the recurrences were straightforward with no karyotypic or morphologic evolution. However, four recur- Table 2 Causes of death beyond 2 years (n = 8) rences among AML patients were somewhat unusual. (1) One patient with t(15;17) transplanted in first remission developed pancytopenia and trilineage dysplasia with del (7) and no t(15;17) at 43 months; RT-PCR for PML-RARA was not performed. The disease evolved into frank AML rapidly. (2) One patient with t(8;21) rescued with GM-CSF-(molgramostim)-mobilized peripheral blood stem cells after failure of primary alloengraftment of unrelated donor marrow 9 relapsed at 50 months with additional del (7) . (3) One patient who had AML-M4 and a normal karyotype at presentation developed a myeloproliferative disease resembling chronic myelomonocytic leukemia 8 months post-transplant, which remained stable for 2 years and then evolved into AML-M4 with a normal karyotype. (4) One patient who had AML-M4 and a normal karyotype at presentation developed progressive pancytopenia and myelodysplasia with a normal karyotype 27 months after BMT. She died of complications of pancytopenia 6 months later without any evidence of recurrent AML on peripheral blood examination.
Cause of death n
Non-relapse deaths
Three patients (3%) died of non-relapse causes at 35, 39 and 40 months ( Table 2) . Two of the deaths were considered to be transplant-related: progressive encephalomyelitis (39 months) and pulmonary fibrosis (40 months). One patient, who had a prior history of ischemic heart disease, died of a myocardial infarct at 35 months. The actuarial 8-year toxic death rate from the 2-year mark is 3% (Figure 2 ).
Overall survival
At the last follow-up, 79 patients (91%) are alive in remission 25-149 months (median 67) after BMT (corresponding to 1-125 months, median 43 months, after the 2-year mark). Seventy-five (86%) are in continuous remission and four are alive after salvage therapy. The actuarial probability of overall survival at 8 years from the 2-year mark is 89% (Figure 1) . The Karnofsky performance scores of the survivors are 80-100% (median 100%). 
Multivariate analysis of prognostic factors
None of the factors analyzed was found to influence the probabilities of survival, relapse, or toxic death, independently.
Renal function
Renal function was normal (serum creatinine Յ110 mol/l) in 77 patients (89%) at the last follow-up in remission. As Table 3 shows, 11% of the patients had an elevated serum creatinine. Only one of them had a creatinine level which was over twice the normal upper limit. Abnormal renal function in this patient was the result of post-transplant refractory thrombotic microangiopathy, 17 and he was not symptomatic from the renal dysfunction.
Liver function
Liver function was normal (serum bilirubin р17 mmol/l) in 73 patients (84%) at the last follow-up in remission. As Table 3 shows, 16% had an elevated bilirubin, 22% an elevated ALT, and 7% an elevated AP. None of the patients was symptomatic from liver dysfunction.
Three of the 10 patients with an elevated creatinine also had some form of liver dysfunction. 
Discussion
Our previously published experience shows that the overwhelming majority of relapses in AML 2,10 and ALL 1, 10, 11 patients transplanted in first remission 1,2 or beyond 10, 11 occurs in the first 2 years. Because of this, it was decided to choose 2 years as an arbitrary time point for evaluation. The current data show that patients with acute leukemia who are alive and well 2 years following an autograft have an excellent probability of long-term survival, with a small chance of relapse and almost negligible risk of late toxic mortality. The incidence of long-term liver and kidney dysfunction, as measured somewhat crudely by the serum bilirubin, ALT, AP, and creatinine values, is low. The quality of life, assessed in a general fashion on the basis of the Karnofsky performance score, is excellent in long-term survivors. The survival is akin to that seen in patients who are alive and well without chronic graft-versus-host disease 2 years following an allograft. 4 Our findings are similar to data from the European Group for Blood and Marrow Transplantation (EBMT) 5 showing that patients with acute leukemia who were alive without disease recurrence at 2 years had event-free survivals of 82% 9 years following transplantation regardless of the nature of the leukemia, the disease stage at transplant, and the type of transplant. Our data and those from the EBMT 5 suggest that 2 years after autotransplantation may be considered an arbitrary landmark for acute leukemia patients, beyond which the likelihood of treatment failure is low, and the probability of being cured is high.
Two of the three non-relapse deaths were clearly due to long-term consequences of the conditioning regimen. Some contribution of the TBI-containing conditioning regimen in the third death from a myocardial infarct cannot be ruled out. However, this patient had a prior history of ischemic heart disease. Therefore it is probably appropriate to consider the death unrelated to the transplant.
An interesting observation in this group of patients was the unusual pattern of disease recurrence in four AML patients with clonal evolution and myelodysplasia or myeloproliferation. While the long-term risk of myelodysplasia is well-known in patients autografted for lymphoma 18, 19 and multiple myeloma, 20 this is not known to be a significant problem in acute leukemia patients. Our data suggest that patients need to be monitored closely for the development of this complication, and that more information is required on long-term hematopoiesis in autografted acute leukemia patients. It has been observed that long-term hematopoiesis is impaired in autografted patients in comparison with allografted patients since the former tend to have lower blood counts than the latter. 21 Three of these patients had received straightforward unpurged marrow grafts. One of these four patients, with t(8;21) at presentation, had received a GM-CSF-mobilized peripheral blood stem cell collection as autologous rescue following primary failure of alloengraftment of unrelated donor marrow. 9, 22 The time to relapse in this patient (50 months) is the longest we have seen in any patient with acute leukemia. The role of cytokine mobilization in the clonal evolution of the disease at relapse [t(8;21) as well as del (7)] remains unknown. This is the only AML patient transplanted with cytokine-mobilized peripheral blood at our center who has survived beyond 2 years; the others experienced rapid relapse. 23, 24 While creatinine clearance would have been a more accurate indicator of renal function, 25 this was not routinely measured. However, the incidence of long-term kidney dysfunction, as measured somewhat crudely by serum creatinine, was low. We have previously reported that although renal function appears normal in these patients, the functional reserve is compromised because when relapsing patients receive chemotherapy and antimicrobial agents, the incidence of renal dysfunction is very high. 25 Serum bilirubin, ALT and AP may be considered adequate indicators of liver function, and were normal in the majority of patients.
The absence of secondary solid tumors is noteworthy, and contrasts with long-term allograft survivors, especially those with chronic GVHD. 4, 26 This would appear to suggest that the allogeneic setting, with chronic GVHD and immunologic disturbances, is more critical to the development of secondary malignancies than factors such as TBI.
We conclude that 2 years after transplantation is an important landmark for autografted adult acute leukemia patients who are alive without relapse because the overwhelming majority of these patients are cured. However, relapses are more common than after allografting. Since there is a small risk of the development of myelodysplasia, these patients should be followed closely with cytogenetic studies in the events of unexplained falls in the blood count or dysplastic features in the blood or marrow.
